Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rafael Rosell

Showing results (91-100 of 565) with videos related to

Pageof 57
Sort By:
Nature Cancer|April 5, 2022
Author Correction: KRAS inhibitors, approvedRafael Rosell, Andrés Aguilar, Carlos Pedraz, et al.
Current Opinion in Oncology|March 7, 2002
Translational oncogenomics: toward rational therapeutic decision-makingRafael Rosell, Mariano Monzo, Aurora O'Brate, et al.
Future Oncology (London, England)|April 3, 2015
Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitorsMariacarmela Santarpia, Giuseppe Altavilla, Vincenzo Pitini, et al.
Critical Reviews in Oncology/Hematology|June 21, 2023
Somatic and germline ATM variants in non-small-cell lung cancer: Therapeutic implicationsJuan-Manuel Hernandez-Martinez, Rafael Rosell, Oscar Arrieta
JAMA Oncology|September 10, 2020
Safety of Anti-PD-L1 Inhibition in HIV-1-Infected Patients With Cancer-ReplyMaria Gonzalez-Cao, Javier Martinez-Picado, Rafael Rosell
Future Oncology (London, England)|March 25, 2006
Crossing the rubicon in lung adenocarcinoma: the conundrum of EGFR tyrosine kinase mutationsRafael Rosell, Enriqueta Felip, Noemí Reguart, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 20, 2007
Platinum resistance related to a functional NER pathwayRafael Rosell, Pedro Mendez, Dolores Isla, et al.
Nature Cancer|February 5, 2022
KRAS inhibitors, approvedRafael Rosell, Andrés Aguilar, Carlos Pedraz, et al.
Cancers|May 13, 2023
Insights into <i>EGFR</i> Mutations and Oncogenic <i>KRAS</i> Mutations in Non-Small-Cell Lung CancerRafael Rosell, Andrés Aguilar-Hernández, María González-Cao
Drugs of Today (Barcelona, Spain : 1998)|December 12, 2003
Influence of genetic markers on survival in non-small cell lung cancerRafael Rosell, Miquel Taron, Carlos Camps, et al.
Pageof 57

Showing results (91-100 of 565) with videos related to

Sort By:
Pageof 57
Nature Cancer|April 5, 2022
Author Correction: KRAS inhibitors, approvedRafael Rosell, Andrés Aguilar, Carlos Pedraz, et al.
Current Opinion in Oncology|March 7, 2002
Translational oncogenomics: toward rational therapeutic decision-makingRafael Rosell, Mariano Monzo, Aurora O'Brate, et al.
Future Oncology (London, England)|April 3, 2015
Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitorsMariacarmela Santarpia, Giuseppe Altavilla, Vincenzo Pitini, et al.
Critical Reviews in Oncology/Hematology|June 21, 2023
Somatic and germline ATM variants in non-small-cell lung cancer: Therapeutic implicationsJuan-Manuel Hernandez-Martinez, Rafael Rosell, Oscar Arrieta
JAMA Oncology|September 10, 2020
Safety of Anti-PD-L1 Inhibition in HIV-1-Infected Patients With Cancer-ReplyMaria Gonzalez-Cao, Javier Martinez-Picado, Rafael Rosell
Future Oncology (London, England)|March 25, 2006
Crossing the rubicon in lung adenocarcinoma: the conundrum of EGFR tyrosine kinase mutationsRafael Rosell, Enriqueta Felip, Noemí Reguart, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 20, 2007
Platinum resistance related to a functional NER pathwayRafael Rosell, Pedro Mendez, Dolores Isla, et al.
Nature Cancer|February 5, 2022
KRAS inhibitors, approvedRafael Rosell, Andrés Aguilar, Carlos Pedraz, et al.
Cancers|May 13, 2023
Insights into <i>EGFR</i> Mutations and Oncogenic <i>KRAS</i> Mutations in Non-Small-Cell Lung CancerRafael Rosell, Andrés Aguilar-Hernández, María González-Cao
Drugs of Today (Barcelona, Spain : 1998)|December 12, 2003
Influence of genetic markers on survival in non-small cell lung cancerRafael Rosell, Miquel Taron, Carlos Camps, et al.
Pageof 57